Introduction
Large granular lymphocytes (LGLs) comprise 10-15% of normal peripheral blood mononuclear cells (PBMC) and are divided into two major lineages based on CD3 expression (Timonen et al., 1981) . CD3
À LGLs are natural killer (NK) cells that do not express the CD3/Tcell receptor (TCR) complex or rearrange TCR genes. Additionally, these cells are capable of mediating non-MHC-restricted cytotoxicity (Lanier et al., 1986) . CD3 þ
LGLs are T cells, which express the CD3/TCR complex and rearrange TCR genes (Ritz et al., 1985) . On the basis of the clonality and invasion of LGLs in marrow, spleen, and liver, we proposed the term ' LGL leukemia' for diseases characterized by increased numbers of circulating LGLs, which can arise for either CD3À or CD3 þ LGLs (Loughran et al., 1985) . Since it is difficult to determine clonality for NK cells, we and others have utilized the term 'lymphoproliferative disease of granular lymphocytes (LDGL)' to encompass NK LGL leukemias (Semenzato et al., 1987; Loughran, 1993) .
NK-LDGL can have an aggressive or a chronic course. Features of aggressive NK-LDGL include large numbers of circulating NK cells, hepatosplenomegaly, and a median survival time of only a few months. Most cases of aggressive NK-LDGL occur in the Far East and are the result of EBV infection (Ohno et al., 1988; Taniwaki et al., 1990) . Patients with chronic NK-LDGL have lymphocytosis that is often associated with bone marrow failure consisting of moderate anemia and/or neutropenia (Tefferi et al., 1994) . Although the etiology of chronic NK-LDGL is not known, patients have high antibody titers to an envelope epitope (BA21) of HTLV-I, suggesting that the disease may be related to an HTLV-like retroviral infection (Loughran et al., 1997) .
Extracellular-regulated kinase (ERK) is a dual specificity kinase that regulates growth and differentiation in response to growth factors (Chang and Karin, 2001) . Growth factors typically activate ERK by a multistep pathway. First, Grb-2/SOS associates with mitogen-activated receptors. Second, receptor-associated Grb-2/SOS recruits and activates Ras, a small farnesylated GTPase. Third, Ras activates Raf, which in turn activates ERK kinase 1 (MEK1). Fourth, MEK1 activates ERK by phosphorylating the TEY motif of ERK (Li et al., 1993) . Through the activation of several antiapoptotic and cell cycle regulatory proteins, phosphorylated ERK elicits growth and survival signals.
Here, we show that NK cells derived from NK-LDGL patients possess cell surface and intracellular markers associated with in vivo activation. This finding suggests that survival signals associated with receptor engagement are active in these cells. Consistent with this premise, we demonstrate constitutive activation of ERK in NK cells from patients with NK-LDGL and the need for ERK activation for the survival of these cells.
Results

Activated phenotype of freshly isolated NK cells from NK-LDGL patients
We determined the expression patterns of CD56 and CD16 on enriched normal NK cells (n ¼ 9) and NK cells derived from NK-LDGL patients (n ¼ 11) by flow cytometry. Of the 13 patients examined, 12 had diagnoses consistent with chronic NK-LDGL (Table 1) . All patients had NK lymphocytosis, and seven had associated bone marrow failure that consisted of either anemia (five out of seven), neutropenia (three out of seven) or both (NKLGL11 and NKLGL13).
As categorized on the basis of CD56 and CD16 expression patterns, normal cells isolated by negative selection contained one major subpopulation (R1) and four minor subpopulations (R2-R5) (Figure 1 ). Cells in the R1 subpopulation expressed large amounts of CD16 and coexpressed CD56 (CD16 high/CD56 þ ). NK cells from NK-LDGL patients were more homogeneous than were normal NK cells, although no one subpopulation predominated ( Figure 1 and Table 2 ). For example, nearly all NK cells from NKLGL6 were of the R2 subtype ( Figure 1 , bottom left), whereas nearly all NK cells from NKLGL8 were of the R3 subtype (Figure 1 , bottom right). NKLGL8 had multiple genetic abnormalities with a diagnosis consistent with aggressive (blastic) LGL leukemia and was the only patient with NK cells limited to the R3 subpopulation. This subpopulation, which expressed CD56 in the absence of CD16, has been shown previously to represent a more immature NK phenotype (Husain et al., 2002) .
We next compared the surface phenotype of normal NK cells and NK cells from patients using two-color flow cytometry to assess the co-expression of CD56, CD16 and the following proteins: HLA-DR, CD45RO, CD11c, CD95, CD11b, CD7, CD25, and CD69. CD45RA was detected on all normal and patient NK cells, whereas CD3 expression was 5% or less (data not shown). In agreement with published data, we found that the majority of NK cells from normal peripheral blood had the following phenotype:
þ (high, average MFI of 7257274), HLA-DR negative, CD11b þ (high, average MFI 2807155), and CD45RO negative (Table 2, average7s.d. of nine normal samples, NL NK) (Lima et al., 2002) .
The surface phenotype of NK cells from NK-LDGL patients differed from that of normal NK cells in four respects. First, NK cells from four out of 12 patients expressed both CD45RO and CD45RA, whereas normal NK cells expressed CD45RA but not CD45RO (Table 2, NKLGL 3, 6, 7, and 8) . Second, NK cells from eight out of 12 patients expressed substantially more HLA-DR than did normal cells (Table 2, NKLGL 1, 3, 4, 5, 6, 8, 10, and 12) . Third, NK cells from all patients expressed less CD11b (MFI 112748) than did normal (Lima et al., 2002) . Thus, the immunophenotype of NK cells from NK-LDGL patients has combined features of both chronic and acute activation. This observation suggests that these cells are activated in vivo by persistent-active infection/activation.
Another measure of NK activation is sensitivity to CD16-mediated apoptosis. Therefore, we compared the sensitivity of normal NK cells and patient NK cells to apoptosis induced by CD16 ligation. In agreement with previous findings (Ortaldo et al., 1995) , anti-CD16 antibody did not appreciably induce the apoptosis of normal NK cells unless they were pretreated with IL-2 (Figure 2 ). On the other hand, 20-40% of NK cells became apoptotic when exposed to anti-CD16 antibody ( Figure 2 ). In agreement with the results of the immunophenotype analyses, the enhanced susceptibility of freshly isolated patient NK cells to CD16-mediated apoptosis suggests that these cells have been sensitized by prior activation in vivo.
Sensivity of NK-LDGL cells to Fas
Large numbers of NK cells accumulate in the peripheral blood of patients with NK-LDGL by an unknown mechanism. Reduced apoptosis rather than increased cellular proliferation has been shown to contribute to the accumulation of T cells in patients with T-LGL leukemia (Lamy et al., 1998) . Thus, we examined the cell cycle profile of NK cells from patients with NK-LDGL. Interestingly, we found that most of the NK cells are in CD69 and CD25 (IL-2Ra) are transiently induced markers of activation after stimulation of NK cells that are associated with proliferation (Montagna et al., 1992; Ferlazzo et al., 2003) . Additional findings from phenotype analysis include little if any CD69 and CD25 expression on NK cells from NK-LDGL patients (Table 2 ) consistent with the G0/G1 phase by cell cycle analysis.
Apoptosis mediated by the Fas receptor is thought to regulate numerous functions of the immune system including the peripheral elimination of activated T cells (Cohen et al., 1992; Miyawaki et al., 1992) . The mechanism that removes activated normal NK cells from circulation is incompletely understood but may involve Fas receptors (Miyawaki et al., 1992; WatanabeFukunaga et al., 1992) . Despite a slightly greater percentage of Fas receptor positive NK cells in patients than in normal (Table 2) , both populations were equally and only minimally sensitive to apoptosis induced by Fas receptor ligation ( Figure 3B ). Exposure of normal (Ac NL) and patient NK cells to IL-2 for a short period of time increased their sensitivity to Fas-induced apoptosis (NK-LGL5, NK-LGL4, NK-LGL7, and NK-LGL10 ( Figure 3B and data not shown). Collectively, the data shown in Figures 2 and 3 suggest that different signaling pathways control Fas-mediated apoptosis and CD16-mediated apoptosis. They also suggest that the failure to become sensitized to Fasmediated apoptosis may contribute to the accumulation of these cells after in vivo activation.
Constitutively active ERK contributes to the survival of NK-LDGL cells
Previous studies have demonstrated the need for ERK activity for the survival of antigen-activated T cells (NL, and PBMCs (containing 48-83% NK) from NK-LDGL patients were exposed to 500 ng/ml anti-Fas agonistic antibody (CH11) (black bars) and 500 ng/ml purified isotype control antibody (gray bars) for 48 h. After activation with IL-2 (100 IU/ml for 72 h), apoptosis of normal NK (AcNL) and patient NKLGL5 cells (AcNKLGL5) is shown as a positive control. The percentage of apoptotic cells is shown7s.d. as described in Material and methods. Asterisk (*) indicates a statistically significant increase from control using a paired T-test (Po0.05). IL-2 sensitization results were reproduced in three additional donors Survival signals in NK-LDGL PK Epling-Burnette et al (Holmstrom et al., 2000) Little is known about the signaling pathways that control the survival of activated NK cells. To address this issue, we first monitored ERK activity in freshly isolated normal and patient NK cells by Western blot analysis using an antibody that specifically recognizes phosphorylated (and thus activate) ERK1 and ERK 2 (collectively referred to as ERK). We found that normal cells lacked detectable ERK activity (Figure 4a, lanes 1 and 3) and that exposure to IL-2 activated ERK (lanes 2 and 4) . In contrast, patient NK cells exhibited ERK activity in the absence of IL-2 (lanes 5, 7, 9, 11, and 13). Incubation of patient cells with the MEK inhibitor PD98059 greatly reduced ERK activity without affecting total ERK levels (lanes 6, 8, 10, 12, and 14) . Cells from two patients were incubated with PD98059 for increasing time to study the kinetic changes in pERK expression (Figure 4b ). We found that the level of pERK was reduced within 12 h. In cells from these two patients and one additional patient, the induction of apoptosis was not observed until 42 h (data not shown). These data suggest that the MEK/ERK pathway is constitutively active in patient NK cells.
We next used MEK inhibitors to evaluate the need for ERK activity for the survival of NK cells from NK-LDGL patients. When exposed to the MEK inhibitors PD98059 and U0126 in vitro, cells from patients exhibited enhanced apoptosis, as shown for a representative donor (Figure 4c ; similar results were obtained for NK cells from four additional patients). Similar doses of these inhibitors had no effect on the survival of normal NK cells (Figure 4c ; these data were reproduced in normal NK cells from two additional donors). In studies of PD98059 specificity and sensitivity, MEK1 and MEK2 were inhibited by 50 mM but this dose failed to inhibit 18 other protein Ser/Thr kinases that included MEK homologues (Alessi et al., 1995) . We found that maximal killing of NK cells from most patients occurred at a concentration of PD98059 of 50 mM (Figure 4d ). PBMC from NK-LGL8 could not be evaluated for sensitivity to the MEK inhibitors due to a high degree of spontaneous cell death at 42 h.
Co-treatment of NK cells from NK-LDGL patients with PD98059 and anti-Fas antibody produced an additive increase in the percentage of apoptotic cells as compared with cells treated with anti-Fas antibody or PD98059 alone (Figure 5a ). As determined by Western blot analysis and/or flow cytometry, PD98059 had no effect on the abundance of Fas receptor, Fas ligand, or ERK2 when added to NK cells from three patients (data not shown).
As another means of assessing the need for ERK activity for the survival of patient NK cells, we infected these cells with vaccinia virus encoding a dominantnegative form of MEK1 (DN-MEK1) (Wei et al., 1998) . As negative controls, other sets of cells were mockinfected or infected with CD56. Infected cells were incubated with or without anti-Fas antibody for 12 h before harvest. At 12 h, a similar (and low) percentage of mock-infected and CD56-control virus-infected cells were apoptotic (Figure 5b) , and CD56 was detected in CD56-infected cells (Figure 5c, panel b ). These results demonstrate that the short infection time (12 h) was sufficient for recombinant protein expression without activation of the viral lytic phase and direct viralinduced cell death.
Expression of DN-MEK1 ablated ERK activity without affecting total ERK levels ( Figure 5c ) and induced the apoptosis of patient NK cells (Figure 5b ). DN-MEK1 in combination with anti-Fas antibody produced an additive increase in apoptosis. Similar results were obtained using cells from four additional patients (data not shown). These results suggest that the MEK/ERK pathway provides signals that promote the survival of NK cells from patients with NK-LDGL.
Ras-dependent ERK activity controls the survival of NK cells from patients with NK-LDGL
In normal NK cells activated by direct target binding, ERK drives lytic activity and mobilization of granzyme B independently of Ras activity . However, Ras activation can be detected during direct target ligation . As shown in Figure 6a , Ras is also constitutively active in NK cells from LDGL patients. Ras activity was determined by GST-Raf-RBD precipitation, and IL-2-treated YT cells, which are NK leukemia cells, are shown as a positive control. Importantly, inhibition of Ras activity in patient NK cells by the farnesyltransferase inhibitor FTI2153 (Lerner et al., 1997; Sun et al., 1999) reduced ERK activity without affecting total amounts of ERK. This finding indicates that Ras contributes to ERK activation in NK cells from NK-LDGL patients.
The need for Ras activity for ERK activation in patient NK cells suggests that inhibition of Ras activity will reduce the survival of these cells, as does inhibition of ERK activity. This premise was confirmed by two methods. First, NK cells from NK-LDGL patients were treated with FTI2153 for 42 h, and the percentage of apoptotic cells was determined. As shown in Figure 6b 
Discussion
NK-LDGL is a lymphoproliferative disease characterized by increased numbers of circulating NK cells. Since NK cells from such patients are not actively cycling, we hypothesize that the accumulation of these cells is due to activation of survival pathways leading to apoptosis resistance. There is currently no standard effective therapy for either the chronic form or aggressive form of LDGL, and these diseases are characteristically resistant to standard forms of chemotherapy. Determination of the molecular signals that promote the survival of patient NK cells will facilitate the design of effective targeted drug therapies and will also provide insights into the mechanisms that regulate the survival of activated normal NK cells.
Here, we report that NK cells from a large majority of patients with NK-LDGL express constitutively active ERK and undergo apoptosis in response to MEK/ERK inhibition. The mechanisms leading to constitutive ERK activation are unknown but may be related to dysregulated NK receptor stimulation. We and others have found that activation of normal NK cells by target binding or by ligation of activation receptors leads to ERK activation (Jiang et al., 2000; Zingoni et al., 2000; McVicar and Burshtyn, 2001; Djeu et al., 2002) . Interestingly, we recently reported a skewed repertoire of NK receptor expression that consisted of predominately activating receptors in this cohort of patients (Epling-Burnette et al., 2004) . We previously found that ERK-dependent tumorcidal function was Ras-independent. In fact, this function required the activation of another GTPase, Rac that activated PAK and ERK . Therefore, it is conceivable that there may be different upstream signaling components that lead to ERK activation in NK cells when comparing survival signaling to cytolytic activity. Cellular recognition and release of granules into a susceptible target requires approximately 15 min and is independent of transcriptional activity. In contrast, Ras may induce a more sustained ERK signal that is required for either enhanced protein stability of antiapoptotic proteins such as those of the Bcl-2 family or in the regulation of transcription factors and other proteins involved in survival. The exact mechanisms and targets of ERK-mediated survival signals are not known. It is known that MEK/ERK signaling suppresses Fasmediated apoptosis in activated T cells by inhibiting DISC-mediated activation of caspase 8. (Holmstrom et al., 2000; Tran et al., 2001; He et al., 2002; Soderstrom et al., 2002) . Other antiapoptotic proteins such as Bcl-2 and BAD are regulated by activated MAPK and may contribute to survival in these NK cells. (Scheid et al., 1999) . We demonstrate here that NK cells from patients with NK-LDGL have an activated phenotype, and it has been proposed that an unknown, perhaps viral, antigen is responsible for expansion of pre-LDGL NK populations (Loughran et al., 1997) . Although these patients are not infected with prototypical HTLV-I or II, sera from most patients react with the BA21 epitope of the p21env protein of HTLV-I (Loughran et al., 1994 (Loughran et al., , 1997 Perzova et al., 2000) . These data suggest that patients with NK-LDGL have been exposed to a protein homologous to BA21, perhaps by infection with a novel retrovirus. Therefore, it is of interest that a synthetic peptide (CKS-17) derived from the p21env of HTLV-I induces ERK activation (Takahashi et al., 2001 ). The data presented here show that a Ras/MEK/ERKdependent pathway contributes to the abnormal survival in NK cells from patients with NK-LDGL. In vitro inhibition of both Ras activity and MEK activity led to increased apoptosis in patient NK cells. The results of preclinical and clinical studies show that FTIs typically inhibit the proliferation of tumor cells without appreciably affecting their survival (Lerner et al., 1995; Sun et al., 1999) . Thus, we found that FTIs uniquely affect quiescent cells with an activated phenotype. New therapeutic strategies are greatly needed, particularly for the aggressive form of NK leukemia. Results of these studies identify the Ras/MEK/ERK signaling pathway as an important molecular target for drug discovery in NK-LDGL and NK leukemia.
Materials and methods
Patients and preparation of PBMC
All patients met the clinical criteria of NK-LDGL with increased numbers of CD3
þ lymphocytes. All patients with chronic disease (n ¼ 11) were clinically stable and untreated at the time of sample acquisition. One patient with aggressive NK leukemia was studied at the time of diagnosis, prior to the initiation of therapy. Informed consents were signed by all patients prior to the use of their cells for these experiments. Buffy coats from nine normal donors were also obtained from the Southwest Florida blood bank. PBMCs were isolated from buffy coats by FicollHypaque gradient separation, as previously described (EplingBurnette et al., 2001) . In some experiments, enriched normal NK cells were isolated from buffy coats by negative selection using RosetteSept, as recommended by the manufacturer (Stem Cell Separation Systems, Vancouver, BC, Canada). We found that these cells contained p1% T cells, p1% monocytes and neutrophils, and p4% B cells. Where indicated, normal and patient NK cells were activated by treatment with 100 U/ml of IL-2 for 1-3 days.
Immunophenotyping
Paired normal and patient NK cells were analysed by two-color flow cytometry using CyChrome-conjugated CD56 (clone B159, BD Biosciences, San Diego, CA, USA) or CD16-fluorescein isothiocyanate (FITC) in combination with the following phycoerythrin (PE)-conjugated antibodies: anti-HLA-DR, anti-CD45RO, anti-CD11c, anti-CD95, antiCD11b, anti-CD7, anti-CD25, and anti-CD69 (all from BD Biosciences). Data acquisition and analysis was carried out on a FACScan flow cytometer (BD Biosciences) using the Cell Quest software program. Forward scatter (FSC) and side scatter (SSC) plots were used to identify the lymphocyte population and a total of 1 Â 10 5 total events were collected. In all samples analysed, the percentage of NK cells within the lymphocyte population was determined by their CD56 and CD16 staining pattern. The percentages of CD56 or CD16 positive cells coexpressing the surface marker of interest (double positive) was determined from the upper right hand quadrant of the flow cytometry dot plot. Mean fluorescence intensity (MFI) of patient NK cells relative to normal NK cells was also determined.
Apoptosis assay
To measure apoptosis, we performed two-color flow cytometry with 7-amino-actinomycin D (7-AAD; Calbiochem-Novabiochem) and annexin-V-FITC (5 ml; BD Pharmingen Transduction Labs., Place), as previously described (Epling-Burnette et al., 2001) . Cell viability was also determined by trypan blue staining and quantitated by labeling with a DNA intercolating dye, 7-AAD, and analysis by flow cytometry. The percent specific apoptosis was calculated using the following formula:
((% annexin-V-FITC positive in the assay well)À (% annexin-V-FITC positive in the control well) Â 100)/(100À (% annexin-V-FITC positive in the control well))
Cell lysis and Western immunoblotting
Cells were lysed in cell lysis buffer and Western blot analysis was performed as previously described (Epling-Burnette et al., 2001) . Antibodies were obtained from the following sources and used at the dilutions recommended by the manufacturer: antiphosphorylated (active) MAPK (ERK1 and 2, New England Biolabs), antitotal MAPK, and antipanRas all from BD Biosciences, and anti-b-actin (Sigma Chemical Co.). Antibody detection was performed by standard ECL techniques as recommended by the manufacturer (Amersham Pharmacia Biotech). Protein quantification was performed by densitometry using the Image Quant program (Molecular dynamics, Sunnyvale, CA, USA).
Detection of activated Ras
To determine the constitutive activation status of Ras in patient NK cells, we used the GST-Raf-RBD-pGEX-KT construct expressed in bacteria to precipitate GTP-bound Ras with glutathione-agarose beads, as previously decribed . Western blot analysis was performed to detect precipitated activated Ras (anti-panRas antibody; BD Pharmingen Transduction Labs).
Vaccinia virus gene delivery
Recombinant vaccinia viruses were constructed using the vector, pSC11, as previously described . For infection, patient NK cells were incubated at a multiplicity of infection of 3 : 1 with either CD56 control virus, DN-MEK1, or DN-Ras (N17Ras) for 2 h. The infected cells were then cultured in the presence of medium alone (control) or medium with 500 ng/ml of anti-Fas agonistic antibody (CH11) for an additional 12 h. Cells were analysed for apoptosis using annexin-V-FITC/7-AAD by flow cytometry.
